Single intravitreal bevacizumab injection effects on contrast sensitivity in macular edema from branch retinal vein occlusion

Arquivos Brasileiros de Oftalmologia

Rony Carlos Preti²  Lisa Mariel Vasquez Ramirez²  Sergio Luis Gianotti Pimentel²  Augusto Alves Lopes Motta²  Cleide Guimarães Machado²  Mário Luiz Ribeiro Monteiro²  Walter Yukihiko Takahashi¹ 

[1],USP Universidade de São Paulo Faculdade de MedicinaSão Paulo SP ,Brazil

关键词: Macular edema;    Retinal vein occlusion;    Contrast sensitivity;    Optical coherence tomography;    Vascular endothelial growth factor A;    Angiogenesis inhibitors;    Antibodies monoclonal;    Visual acuity;    Injections;    Edema Macular;    Oclusão da veia retiniana;    Sensibilidade de contraste;    Tomografia de coerência óptica;    Fator A de crescimento do endotélio vascular;    Inibidores da angiogênese;    Anticorpos monoclonais;    Acuidade visual;    Injeções;   

DOI  :  10.1590/S0004-27492012000100006

来源: SciELO

【 摘 要 】

PURPOSE: To evaluate the effect of a single intravitreal bevacizumab injection on visual acuity, contrast sensitivity and optical coherence tomography-measured central macular thickness in eyes with macular edema from branch retinal vein occlusion. METHODS: Seventeen eyes of 17 patients with macular edema from unilateral branch retinal vein occlusion were treated with a single bevacizumab injection. Patients were submitted to a complete evaluation including best corrected visual acuity, contrast sensitivity and optical coherence tomography measurements before treatment and one and three months after injection. Visual acuity, contrast sensitivity and optical coherence tomography measurements were compared to baseline values. RESULTS: Mean visual acuity measurement improved from 0.77 logMAR at baseline to 0.613 logMAR one month after injection (P=0.0001) but worsened to 0.75 logMAR after three months. Contrast sensitivity test demonstrated significant improvement at spatial frequencies of 3, 6, 12 and 18 cycles/degree one month after injection and at the spatial frequency of 12 cycles/degree three months after treatment. Mean ± standard deviation baseline central macular thickness (552 ± 150 µm) reduced significantly one month (322 ± 127 µm, P=0.0001) and three months (439 ± 179 µm, P=0.01) after treatment. CONCLUSIONS: Bevacizumab injection improves visual acuity and contrast sensitivity and reduces central macular thickness one month after treatment. Visual acuity returns to baseline levels at the 3-month follow-up, but some beneficial effect of the treatment is still present at that time, as evidenced by optical coherence tomography-measured central macular thickness and contrast sensitivity measurements.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License